Hyderabad,: AstraZeneca India has entered into a Memorandum of Understanding (MoU) with the Government of Telangana to advance the adoption of AI-powered lung cancer screening across public hospitals in the state, marking a significant step towards early detection and improved cancer care outcomes.

The collaboration aims to leverage artificial intelligence and advanced diagnostic technologies to enhance the early identification of lung cancer, one of the leading causes of cancer-related mortality worldwide. The initiative will focus on integrating AI tools into existing healthcare infrastructure to support timely diagnosis, risk assessment, and clinical decision-making.

Under the MoU, the program is expected to strengthen screening capabilities in government hospitals, particularly benefiting patients in underserved and high-risk populations. The use of AI-driven systems will enable faster analysis of imaging data, helping clinicians detect abnormalities at an earlier stage and initiate prompt treatment.

Officials highlighted that early detection is critical in improving survival rates in lung cancer, and the deployment of AI technologies can significantly reduce diagnostic delays and improve accuracy. The initiative will also include capacity building, training of healthcare professionals, and system integration to ensure effective implementation.

AstraZeneca stated that the partnership reflects its commitment to advancing oncology care through innovation and collaboration, while supporting public health systems with scalable and technology-driven solutions.

The Telangana government emphasized that the initiative aligns with its broader vision of strengthening public healthcare infrastructure through digital health adoption, ensuring better access to quality care for all citizens.

Experts believe that such public-private partnerships are crucial in accelerating the adoption of AI in healthcare, enabling more efficient, accessible, and patient-centric care delivery models.

With this collaboration, Telangana takes another step forward in positioning itself as a leader in healthcare innovation, while addressing the growing burden of cancer through early detection and advanced technology.